These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 25592064)
21. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
22. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359 [TBL] [Abstract][Full Text] [Related]
23. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Yang TM; Barbone D; Fennell DA; Broaddus VC Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992 [TBL] [Abstract][Full Text] [Related]
24. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615 [TBL] [Abstract][Full Text] [Related]
25. YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells. Woo SM; Min KJ; Seo BR; Seo YH; Jeong YJ; Kwon TK Mol Cell Biochem; 2017 May; 429(1-2):91-102. PubMed ID: 28120212 [TBL] [Abstract][Full Text] [Related]
26. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561 [TBL] [Abstract][Full Text] [Related]
27. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663 [TBL] [Abstract][Full Text] [Related]
28. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792 [TBL] [Abstract][Full Text] [Related]
29. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak. Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383 [TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017 [TBL] [Abstract][Full Text] [Related]
32. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Hauck P; Chao BH; Litz J; Krystal GW Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561 [TBL] [Abstract][Full Text] [Related]
33. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Zhang C; Cai TY; Zhu H; Yang LQ; Jiang H; Dong XW; Hu YZ; Lin NM; He QJ; Yang B Mol Cancer Ther; 2011 Jul; 10(7):1264-75. PubMed ID: 21566062 [TBL] [Abstract][Full Text] [Related]
34. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Premkumar DR; Jane EP; Pollack IF Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928 [TBL] [Abstract][Full Text] [Related]
35. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096 [TBL] [Abstract][Full Text] [Related]
36. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698 [TBL] [Abstract][Full Text] [Related]
37. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063 [TBL] [Abstract][Full Text] [Related]
38. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Huang S; Sinicrope FA Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764 [TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Spender LC; Inman GJ Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218 [TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]